GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wakamoto Pharmaceutical Co Ltd (TSE:4512) » Definitions » Research & Development

Wakamoto Pharmaceutical Co (TSE:4512) Research & Development : 円0 Mil (TTM As of Mar. 2025)


View and export this data going back to 1949. Start your Free Trial

What is Wakamoto Pharmaceutical Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Wakamoto Pharmaceutical Co's Research & Development for the three months ended in Mar. 2025 was 円0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was 円0 Mil.


Wakamoto Pharmaceutical Co Research & Development Historical Data

The historical data trend for Wakamoto Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wakamoto Pharmaceutical Co Research & Development Chart

Wakamoto Pharmaceutical Co Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Wakamoto Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Wakamoto Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wakamoto Pharmaceutical Co  (TSE:4512) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Wakamoto Pharmaceutical Co Research & Development Related Terms

Thank you for viewing the detailed overview of Wakamoto Pharmaceutical Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Wakamoto Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
2-2-2, Nihonbashi Honcho, Chuo-ku, Tokyo, JPN, 103-8330
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.

Wakamoto Pharmaceutical Co Headlines

No Headlines